Valuation: Moderna, Inc.

Market Cap 55.45B 47.52B 44.46B 40.64B 76.7B 5,309B 77.51B 526B 205B 2,666B 208B 204B 8,821B P/E 2026 *
-16.2x
P/E 2027 * -28.5x
Enterprise Value 51.8B 44.39B 41.53B 37.97B 71.65B 4,960B 72.41B 491B 191B 2,491B 194B 190B 8,241B EV / Sales 2026 *
24.6x
EV / Sales 2027 * 21.7x
Free-Float
92.68%
Yield 2026 *
-
Yield 2027 * -
1 day+11.92%
1 week+142.74%
Current month+169.22%
1 month+170.07%
3 months+222.61%
6 months+198.62%
Current year+398.94%
1 week 54.17
Extreme 54.17
142.38
1 month 45.93
Extreme 45.93
142.38
Current year 25.41
Extreme 25.41
142.38
1 year 19.37
Extreme 19.374
142.38
3 years 19.37
Extreme 19.374
156.54
5 years 19.37
Extreme 19.374
392.9
10 years 19.37
Extreme 19.374
426.45
Manager TitleAgeSince
Chief Executive Officer 54 2011-02-28
Director of Finance/CFO 49 2022-09-05
President 50 2024-10-31
Director TitleAgeSince
Chairman 63 2012-01-31
Director/Board Member 54 2011-02-28
Director/Board Member 69 2019-12-10
Change 5-day change 1-year change 3-year change Capi.($)
+12.01%+142.74% - - 55.45B
+0.89%+2.94%+45.72%+0.45% 82.73B
+2.68%+29.00%-19.83%-34.19% 57.94B
+11.47%+144.53%+507.32%+37.55% 55.45B
+0.76%+2.39%+0.08%+35.11% 52.57B
+1.91%+2.95%+11.29%+173.87% 48.94B
+0.80%+3.66%+61.58%-16.68% 32.23B
+2.07%+5.53%+53.72%+104.03% 25.94B
+0.60%+4.98%+0.65%+188.89% 22.1B
+3.52%+0.77%+61.34%+111.47% 16.55B
Average +3.62%+17.75%+80.21%+66.72% 43.83B
Weighted average by Cap. +3.99%+21.99%+90.58%+47.34%

Financials

2026 *2027 *
Net sales 2.11B 1.81B 1.69B 1.54B 2.91B 202B 2.94B 19.98B 7.77B 101B 7.91B 7.74B 335B 2.46B 2.11B 1.97B 1.8B 3.4B 235B 3.44B 23.31B 9.06B 118B 9.23B 9.03B 391B
Net income -3.38B -2.9B -2.71B -2.48B -4.67B -324B -4.72B -32.06B -12.46B -162B -12.69B -12.41B -538B -1.9B -1.62B -1.52B -1.39B -2.62B -181B -2.65B -17.98B -6.99B -91.13B -7.12B -6.96B -302B
Net Debt -3.65B -3.13B -2.93B -2.67B -5.05B -349B -5.1B -34.62B -13.46B -175B -13.7B -13.4B -581B -2.19B -1.88B -1.76B -1.61B -3.03B -210B -3.07B -20.81B -8.09B -105B -8.24B -8.06B -349B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
26-08-25 132.32 +11.76% 67,129
26-08-24 €118.40 -8.99% 49,830
26-08-21 €130.10 +6.81% 105,019
26-08-20 €121.80 +1.10% 185,317
26-08-19 €120.48 +121.02% 208,950
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
138.89USD
Average target price
95.67USD
Spread / Average Target
-31.12%

Quarterly revenue - Rate of surprise